...
首页> 外文期刊>Neurosurgical focus >Colao A, Di Sarno A, Cappabianca P, et al: Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023–2033, 2003
【24h】

Colao A, Di Sarno A, Cappabianca P, et al: Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023–2033, 2003

机译:Colao A,Di Sarno A,Cappabianca P等:撤消长期卡麦角林治疗肿瘤和非肿瘤性高泌乳素血症的方法。英格兰医学杂志349:2023-2033,2003年

获取原文
           

摘要

Background Whether the withdrawal of treatment in patients with nontumoral hyperprolactinemia, microprolactinomas, or macroprolactinomas is safe and effective has been unclear. We performed an observational, prospective study of cabergoline (a dopamine-re
机译:背景技术对于非肿瘤性高泌乳素血症,微泌乳素瘤或大泌乳素瘤患者,退出治疗是否安全,有效尚不清楚。我们进行了卡麦角林(多巴胺再

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号